Publications by authors named "Jianzhen Teng"
It is controversial whether hemodialysis affects the efficacy of the antiplatelet agents. We aimed to investigate the impact of hemodialysis on efficacies of the antiplatelet agents in coronary artery disease (CAD) patients complicated with end-stage renal disease (ESRD). 86 CAD patients complicated with ESRD requiring hemodialysis were consecutively enrolled.
View Article and Find Full Text PDFBackground: Currently, noninvasive arteriography for the diagnosis of coronary artery disease is clinically limited to the computed tomography scanning, where patients have to be exposed to the radiation and risks associated with iodinated contrast. We aimed to investigate the diagnostic performance and safety of a novel ferumoxytol-enhanced coronary magnetic resonance angiography (CMRA) in patients with suspected coronary artery disease.
Methods: Thirty patients, 19 males, with a median age of 63 years old, and 17 with renal insufficiency, who were scheduled for invasive coronary angiography, were enrolled.
Previous studies have suggested that proton pump inhibitors could impair the antiplatelet effect of clopidogrel. It is uncertain whether ilaprazole affects the antiplatelet effect of clopidogrel. This study aimed to determine the drug-drug interaction between ilaprazole and clopidogrel.
View Article and Find Full Text PDFObjective: This study was aimed to determine how platelet reactivity (PR) on dual antiplatelet therapy predicts ischemic and bleeding events in patients underwent percutaneous coronary intervention (PCI).
Design: A total of 2768 patients who had received coronary stent implantation and had taken aspirin 100 mg in combination with clopidogrel 75 mg daily for > 5 days were consecutively screened and 1885 were enrolled. The recruited patients were followed-up for 12 months.
Article Synopsis
- High on-treatment platelet reactivity (HOPR) in post-PCI patients increases the risk of cardiovascular events, leading to a study on intensified dual antiplatelet therapy (DAPT).
- 434 patients with HOPR were randomized to receive intensified therapy (different combinations of clopidogrel and aspirin) for 1 month versus standard therapy (clopidogrel 75 mg).
- The results showed that the intensified therapy significantly reduced the rate of persistent HOPR and major adverse cardiovascular events (MACE) at both 1 and 12 months, without a significant increase in bleeding risks.
Doxorubicin is one of the most important chemotherapeutic drugs for the treatment of malignant tumors, but the cardiotoxicity of doxorubicin severely limits its clinical application. Increasing numbers of microRNAs (miRNAs/miRs) have been found to be dysregulated in doxorubicin‑treated cardiomyocytes or animal hearts. The current study aimed to investigate the role of miR‑133b in doxorubicin‑induced cardiomyocyte injury.
View Article and Find Full Text PDF